Predictive performance of the clinicopathologic gene expression profile (CP-GEP) in identifying cutaneous melanoma patients for whom sentinel lymph node biopsy is unnecessary: A systematic review and meta-analysis
Open Access
- 20 June 2025
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 214, 104816
Abstract
No abstract availableKeywords
Funding Information
- SkylineDx BV
This publication has 44 references indexed in Scilit:
- Risk Prediction Models for Sentinel Node Positivity in MelanomaJAMA Dermatology, 2025
- iMLGAM: Integrated Machine Learning and Genetic Algorithm‐driven Multiomics analysis for pan‐cancer immunotherapy response predictioniMeta, 2025
- Navigating the immune landscape with plasma cells: A pan‐cancer signature for precision immunotherapyBioFactors, 2024
- Clinical evaluation of the clinicopathologic and gene expression profile (CP-GEP) in patients with melanoma eligible for sentinel lymph node biopsy: A multicenter prospective Dutch studyEuropean Journal of Surgical Oncology, 2023
- Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040JAMA Dermatology, 2022
- Differences in Thickness-Specific Incidence and Factors Associated With Cutaneous Melanoma in the US From 2010 to 2018JAMA Oncology, 2022
- Validation of a clinicopathological and gene expression profile model to identify patients with cutaneous melanoma where sentinel lymph node biopsy is unnecessaryEuropean Journal of Surgical Oncology, 2022
- Sentinel lymph node biopsy in patients with thin melanomas: Frequency and predictors of metastasis based on analysis of two large international cohortsJournal of Surgical Oncology, 2018
- Complications of sentinel lymph node biopsy for melanoma – A systematic review of the literatureEuropean Journal of Surgical Oncology, 2017
- Validation of a nomogram predicting sentinel lymph node status in melanoma in an Irish populationIrish Journal of Medical Science (1971 -), 2014